Frontiers in Oncology

From Intern to Chief: A Tale of Partnerships and Persistence with a Vision for the Future

Heather Wakelee, MD⁣⁣
Tuesday, October 20, 2020⁣⁣

Dr. Heather Wakelee is a Professor of Medicine in the Division of Oncology at Stanford University and is the faculty director of the Stanford Cancer Clinical Trials Office. Dr. Wakelee has authored or co-authored over 200 medical articles on lung cancer and other thoracic malignancies and is involved in dozens of clinical trials related to lung cancer therapy and diagnostics. Her research focuses on many specific lung cancer subtypes defined by specific mutations in EGFR, ALK, ROS1, RET, BRAF, and others. She is also involved in trials of adjuvant therapy, immunotherapy, and anti-angiogenesis agents in addition to collaborations with colleagues focused on biomarkers and others focused on population science research.⁣


Dr. Wakelee is active in multiple national and international lung cancer research organizations including serving as a member of the Board of Directors of the International Association for the Study of Lung Cancer (IASLC), co-chair of the thoracic committee, and Stanford Principal Investigator for the Eastern Cooperative Oncology Group (ECOG-ACRIN), and as a Fellow of the American Society of Clinical Oncology (FASCO).⁣

Frontiers in Oncology

Frontiers in Oncology, a recurring seminar series organized by the Stanford Cancer Institute, is designed to highlight innovations in cancer research across the spectrum of basic, translational, clinical and population science.  The dynamic speakers represent a broad range of disciplines and expertise from both Stanford faculty and national thought leaders.  The audience for this seminar series includes Stanford faculty, trainees and staff as well as anyone in the broader community with an interest in cancer research.  Each recorded seminar is approximately 1 hour in length.